Amicus Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $154,688 | $125,249 | $149,706 | $141,517 |
Gross Profit | 139,471 | 113,551 | 134,870 | 128,238 |
EBITDA | -5,764 | -4,753 | 21,933 | 21,647 |
EBIT | -7,616 | -6,590 | 19,892 | 19,477 |
Net Income | -24,420 | -21,686 | 14,739 | -6,729 |
Net Change In Cash | 154,688 | 125,249 | 149,706 | 141,517 |
Free Cash Flow | -28,929 | 7,546 | -4,204 | -23,327 |
Cash | 158,702 | 181,657 | 213,752 | 233,647 |
Basic Shares | 307,972 | 307,689 | 304,380 | 304,691 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $528,295 | $399,356 | $329,233 | $305,514 |
Gross Profit | 475,352 | 362,030 | 290,634 | 271,048 |
EBITDA | 29,389 | -92,079 | -199,578 | -202,874 |
EBIT | 20,842 | -99,952 | -204,920 | -209,083 |
Net Income | -56,106 | -151,584 | -236,568 | -250,460 |
Net Change In Cash | 528,295 | 399,356 | 329,233 | 305,514 |
Cost of Revenue | -81,722 | 88,343 | ||
Free Cash Flow | -37,444 | -76,531 | -170,341 | -206,375 |
Cash | 213,752 | 246,994 | 148,813 | 245,197 |
Basic Shares | 304,381 | 295,164 | 289,057 | 271,421 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.01 |
2025-03-31 | $0.03 |
2024-12-31 | $0.09 |
